**Chapter 7**

*Lupus - Need to Know*

[148] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. Jun 2019;78(6):736-745. doi:10.1136/ annrheumdis-2019-215089

[149] Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. *Arthritis Rheumatol*. Feb

[150] Merrill JT, Furie R, Werth VP, et al.

[151] Lateef A, Petri M. Biologics in the

erythematosus. *Curr Opin Rheumatol*. Sep 2010;22(5):504-9. doi:10.1097/

[152] Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind,

randomised, placebo-controlled, phase 2 trial. *Lancet*. Jul 21 2018;392(10143):222- 231. doi:10.1016/s0140-6736(18)31363-1

treatment of systemic lupus

BOR.0b013e32833b475e

2017;69(2):376-386. doi:10.1002/

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. *Lupus Sci Med*. 2018;5(1):e000284. doi:10.1136/

lupus-2018-000284

art.39962

**130**
